Blood test could personalize chemo breaks for advanced colon cancer

NCT ID NCT06446557

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to reduce or switch chemotherapy in people with metastatic colorectal cancer. About 408 participants will be randomly assigned to either standard treatment or a strategy where ctDNA levels guide whether they stop chemo, continue with a milder maintenance, or switch drugs. The goal is to see if the ctDNA-guided approach improves survival while maintaining quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy plus targeted agent (anti-EGFR or bevacizumab)

What this could lead to

If successful, this could show that using a simple blood test to guide treatment decisions improves survival and quality of life for people with metastatic colorectal cancer.

What could go wrong

This is a large phase 3 trial, but it only includes a specific subset of patients (left-sided, MSS, BRAF wild-type). The ctDNA test may not work as expected, and the experimental strategy could be no better or even worse than standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer malignant colon neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de ROUEN

    Rouen, 76031, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact